Based on these findings, CXCL10 has been speculated as a plasma inflammatory biomarker of immune activation in both viremic and aviremic HIV patients on cART therapy (Kamat et al., 2012) and, was found to be associated with a more rapid HIV/SIV neurological disease progression via the influx of CXCR3+ cells in the CNS (Ploquin et al., 2016). The gene discussed is CXCR3; the disease is nervous system disorder.